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INTRODUCTION
The accurate prediction of pathologic stage in cancer 
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Objective: The purpose of the current study was to develop support vector machine (SVM) and artificial neural network 
(ANN) models for the pre-operative prediction of advanced prostate cancer by using the parameters acquired from 
transrectal ultrasound (TRUS)-guided prostate biopsies, and to compare the accuracies between the two models.
Materials and Methods: Five hundred thirty-two consecutive patients who underwent prostate biopsies and prostatectomies 
for prostate cancer were divided into the training and test groups (n = 300 versus n = 232). From the data in the training 
group, two clinical decision support systems (CDSSs-[SVM and ANN]) were constructed with input (age, prostate specific 
antigen level, digital rectal examination, and five biopsy parameters) and output data (the probability for advanced prostate 
cancer [> pT3a]). From the data of the test group, the accuracy of output data was evaluated. The areas under the receiver 
operating characteristic (ROC) curve (AUC) were calculated to summarize the overall performances, and a comparison of the 
ROC curves was performed (p < 0.05).
Results: The AUC of SVM and ANN is 0.805 and 0.719, respectively (p = 0.020), in the pre-operative prediction of advanced 
prostate cancer.
Conclusion: The performance of SVM is superior to ANN in the pre-operative prediction of advanced prostate cancer.
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management is important in choosing an adequate 
treatment plan. Accurate staging is critical for prostate 
cancer because the majority of men diagnosed with 
prostate cancer are older adults with other co-morbidities 
(1). However, cancer staging performed by a physician 
may be subjective, and therefore depends heavily on 
experience, skill, and knowledge. Within this background, 
various clinical decision support systems (CDSSs) derived 
from computerized machine learning techniques have 
been introduced as unbiased and objective supporters for 
decision-making. 
There have been several studies to improve the prostate 
cancer detection rate with the use of prediction models 
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based on logistic regression analysis and an artificial 
neural network (ANN) (2-11). The use of a support vector 
machine (SVM) approach has been introduced as a potential 
alternative to conventional ANNs (2, 12). SVMs have 
attracted attention as a useful tool for image recognition 
and bioinformatics by defining the optimal separating 
hyperplane with the maximal margin. 
Many predictive models to predict pathologic stage 
have been developed on the basis of different parameters 
of transrectal ultrasound (TRUS)-guided prostate biopsy 
(13). However, no report is available on the pre-operative 
prediction of advanced prostate cancer based on prostate 
biopsy by applying CDSSs, such as SVM and ANN models, 
in spite of the advancement in solving classification 
problems. Moreover, a comparison study between a SVM and 
other established CDSSs, such as an ANN, on the accurate 
prediction of advanced prostate cancer with parameters 
acquired from prostate biopsy is needed.
The purpose of this study was to develop SVM and 
ANN models for the pre-operative prediction of advanced 
prostate cancer with the parameters of TRUS-guided 
prostate biopsies and to compare the accuracies of each 
model.
MATERIALS AND METHODS
Patient Selection
Our Institutional Review Board approved this retrospective 
study and waived the requirement for informed consent. 
Between May 2003 and May 2008, 532 consecutive patients 
who underwent TRUS prostate biopsies and subsequent 
radical prostatectomies due to prostate cancer were enrolled 
in this study.
The indications to perform biopsies included a high 
prostate specific antigen (PSA) level > 4.0 ng/mL, abnormal 
digital rectal examination (DRE) finding and/or positive 
TRUS findings. The patients who underwent repeat biopsy 
with negative biopsy results previously were not included 
in the study. The mean age of the patients was 64.8 ± 6.6 
years (range, 38-80 years).
The patients were divided into a training (n = 300) and 
test group (n = 232) using random sampling with a table 
of random numbers. The training group was designated for 
constructing CDSSs, and the test group was designated for 
the evaluation of accuracies in each CDSS.
Before obtaining biopsies, pre-operative DREs were 
performed by an urologist with 25 years of experience. 
Nodular palpation on DRE was considered positive. A simple, 
enlarged prostate or non-palpable nodular lesion in the 
prostate was classified as negative.
Transrectal US-Guided Prostate Biopsy 
Transrectal US-guided prostate biopsies were performed 
by a radiologist specializing in the genitourinary tract 
(10 years of experience). Before performing TRUS-guided 
biopsies, local anesthetic was administered via a 22-gauge, 
13.97-cm Chiba needle (Becton Dickinson, Franklin Lakes, 
NJ). An 18-gauge, 20-cm automatic cutting needle and 
automated biopsy gun (Pro-Mag 2.2; Manan Medical 
Products, Northbrook, IL) were used to obtain biopsy cores. 
Biopsy specimens were generally obtained from 12 separate 
randomized prostate regions, including three samples from 
the peripheral zone and three samples from the inner gland 
on each side. In cases in which focal lesions were detected 
on TRUS, biopsies encompassing the lesions were obtained. 
The biopsy specimen was numbered to match the focal 
lesion.
Five biopsy parameters from systematic needle biopsy 
results were obtained, as follows: number of positive cores 
for cancer; percentage of positive biopsy cores; total linear 
cancer length (absolute sum of the tumor length at each 
core); percentage cancer length (total cancer length divided 
by the total length of cores obtained x 100); and maximum 
cancer core length.
Histopathologic Analysis
The histopathologic analyses of biopsy specimens and 
extirpated prostates were performed by a pathologist 
specializing in genitourinary system with more than 20 
years of experience. All of the extirpated prostates were 
obtained by radical retropubic prostatectomies. Routine 
sections of all surgical margins, including the prostate base 
and apex, urethra, bladder neck, capsule and peri-prostatic 
soft tissue, each seminal vesicle, lymph nodes from bilateral 
pelvic lymph node dissection, and the peripheral zones 
of the right and left prostate lobes, were examined as 
permanent sections.
Construction of Clinical Decision Support Systems 
From the data in the training group, we constructed SVM 
and ANN models. The input parameters were three clinical 
and five TRUS parameters, as follows: age; PSA level; DRE 
findings; number of positive cores for cancer; percentage of 
positive biopsy cores; total linear cancer length (absolute 
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sum of tumor length at each core); percentage cancer 
length (total cancer length divided by total length of cores 
obtained x 100); and maximum cancer core length. The 
output data were the probability for advanced prostate 
cancer (more than pT3a). From the data of the test group, 
the accuracy of output data was evaluated.
We constructed an ANN model that consisted of a three-
layered perceptron architecture. The ANN model was 
developed by extending the multilayer perceptron (MLP) 
source code written by Jiang and Manry (ftp.simtel.net/
pub/simtelnet/msdos/calculte/Nuclass706a.zip) (2, 14). 
The neural network consisted of one input layer, one hidden 
layer, and one output layer. The ANN that was used in our 
study was composed of eight input nodes in the input layer, 
10 hidden nodes in the hidden layer, and 1 output node 
in the output layer. The number of nodes was determined 
by trial and error to produce the best performance. The 
iteration number of back propagation updating was 
500, which was determined to balance the accuracy and 
calculation speed. During a training process, the connection 
weights between the neurons were adjusted by use of the 
back propagation-updating algorithm.
The ANN was trained using the data of the training group 
(n = 300) to produce a value of 1 for an advanced prostate 
cancer (more than pT3a) and -1 for a confined prostate 
cancer. As the direct output value of the ANN does not 
show probability, we converted the output value to the 
probability by applying a sigmoid function as follows: P(x) 
= 1/(1 + e-x), where x is the output value of the ANN. The 
value of P indicates the probability that the patient has 
advanced prostate cancer (more than pT3a). The output 
data were analyzed in percentage terms.
An SVM has been proposed in which the model should 
be used for classification and regression (15). The SVM is 
based on the use of powerful statistical theory. We used 
the LIBSVM provided by Chang and Lin on the website 
(16). LIBSVM is integrated software for support vector 
classification, regression, and distribution estimation and 
LIBSVM supports multi-class classification (2).
In our study, we applied the use of LIBSVM to two class 
problems (advanced or confined cancers). Unlike the 
ANN, the SVM does not require a trial and error parameter 
decision process. The SVM determines optimal performance 
conditions automatically if the kernel type is set. The 
decision hyperplane that separates advanced and confined 
prostate cancers constructed by SVM shows theoretical 
optimal separability concerning the training data. 
The SVM received eight input data from the training group 
(n = 300) and one output value from each patient, and was 
trained to produce a value of 1 for an advanced prostate 
cancer and a -1 for a confined prostate cancer. Similar to 
the ANN, the output values of the SVM were converted to 
probabilities by applying a sigmoid function. The value of 
P indicates the probability that the patient has advanced 
prostate cancer (more than pT3a). The output data were 
analyzed in percentage terms.
Data Analysis
The accuracy of output data were evaluated with data 
from each test group (n = 232). The receiver operating 
characteristic (ROC) curve and the area under the curve 
(AUC) were used as performance indices. An ROC graph is 
a technique for visualizing the performance of classifiers 
and is useful to compare the performance of different 
classifiers in medical decision-making systems. In this 
study, the performances of the SVM and ANN models were 
evaluated using ROC analysis to predict the probabilities 
of the pathologic stage of prostate cancer. The ROC curves 
were estimated using MedCalc statistical software (version 
9.6.2.0; MedCalc Software, Mariakerke, Belgium). The 
sensitivities, specificities, and accuracies of two CDSSs were 
calculated. The AUC was calculated to summarize the overall 
performances. Comparison of ROC curves was performed. A p 
value < 0.05 indicated a statistically significant difference.
RESULTS
Parameters of the Training and Test Groups
Table 1 shows the means and standard deviations (SD) 
of the training and test groups. In the training group, the 
average patient age was 65.2 ± 6.5 years (range, 38-80 
years). The mean PSA value was 11.97 ± 13.26 ng/mL (range, 
1.1-94.4 ng/mL). The percentage of DRE-positive cases was 
27%. The mean number of positive cores for cancer was 4.5 
± 3.3. The mean percentage of positive biopsy cores was 
35 ± 25.1% (range, 5-100%). The mean total linear cancer 
length was 2.23 ± 2.89 cm (range, 0.02-19.8 cm). The mean 
percentage cancer length was 27 ± 17.5% (range, 1-88%). 
The mean maximum cancer core length was 0.64 ± 0.44 cm 
(range, 0.02-1.9 cm).
In the test group, the average patient age was 64.3 ± 6.8 
years (range, 42-76 years). The mean PSA value was 11.88 
± 21.23 ng/mL (range, 0.2-216.3 ng/mL). The percentage 
of DRE-positive cases was 23%. The number of positive 
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cores for cancer was 3.4 ± 3.0. The mean percentage of 
positive biopsy cores was 27 ± 23.1% (range, 6-100%). The 
mean total linear cancer length was 1.45 ± 2.38 cm (range, 
0.02-16.0 cm). The mean percentage cancer length was 21 
± 14.6% (range, 1-77%). The mean maximum cancer core 
length was 0.47 ± 0.39 cm (range, 0.02-1.9 cm). 
The percentage of advanced prostate cancer (more than 
pT3a) in the training and test groups were 31% and 27%, 
respectively (Table 1).
Performance of the Decision Models
Figure 1 shows the ROC curves for the use of SVM and 
ANN. The sensitivity, specificity, and accuracy of SVM 
were 67%, 79%, and 77%, respectively. The sensitivity, 
specificity, and accuracy of ANN were 63%, 81%, and 78%, 
respectively. The AUC for use of the SVM and ANN were 
0.805 and 0.719, respectively. Comparison of the ROC 
curves demonstrated that there was a statistical difference 
between use of the SVM and ANN (p = 0.020; Fig. 1). In 
the pre-operative prediction of advanced prostate cancer, 
performance of the SVM was statistically superior to ANN.
DISCUSSION
Based on the concept that prostate cancer volume is 
correlated strongly with local invasiveness, metastatic 
potential, and a loss of histologic differentiation, 
various quantitative parameters from needle biopsy 
results have been assessed to predict pathologic stage in 
radical retropubic prostatectomy (17). The current study 
demonstrated that multiple logistic regression analysis of 
our quantitative parameters for predicting stage indicated 
that maximum cancer length is a unique independent 
predictor of organ-confined disease. ROC curve analysis 
found that “length-parameters”, such as maximum cancer 
length, total linear cancer length, and percentage cancer 
length, were significantly superior to “number-parameters”, 
including number of cores positive and percentage of cores 
positive. Furthermore, ROC curve analysis also revealed that 
percentage cancer length had a similar performance for 
predicting pathologic stage to total linear cancer length 
(13).
The combined use of the serum PSA level, the biopsy 
Gleason score, and biopsy parameters is advocated to 
Table 1. Mean and Standard Deviations of Input Parameters in Training and Test Groups
Mean (± SD)
Training Group (n = 300) Test Group (n = 232) Total (n = 532)
Age (Year) 65.2 (6.5) 64.3 (6.8) 64.8 (6.6)
Total PSA (ng/mL) 11.97 (13.26) 11.88 (21.23) 11.93 (17.13)
Percentages of DRE-positive (%) 82 (27) 53 (23) 135 (25)
Mean number of positive cores 4.5 (3.3) 3.4 (3.0) 4.0 (3.2)
Mean percentage of positive biopsy core (%) 34.7 (25) 26.6 (23) 31.2 (25)
Mean total linear cancer length (cm) 2.23 (2.89) 1.45 (2.38) 1.90 (2.71)
Mean percentage cancer length (%) 26.6 (18) 20.5 (15) 24.0 (17)
Mean maximum cancer core length (cm) 0.64 (0.44) 0.47 (0.39) 0.57 (0.43)
Percentages of advanced prostate cancer (%) 94 (31) 62 (27) 156 (29)
Note.— DRE = digital rectal examination, PSA = prostate specific antigen, SD = standard deviation
Fig. 1. Receiver operating characteristic (ROC) curve analysis 
of clinical decision support systems using support vector 
machine (SVM) and artificial neural network (ANN) models. 
Area under ROC curve (AUC) value of SVM was superior to ANN.
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improve the pre-operative predictability of final pathologic 
stage. Park et al. (13) reported that the maximum cancer 
length in combination with the PSA level and Gleason 
score improves pathologic stage predictability by ROC 
curve analysis (18-21). In our study, biopsy parameters and 
various clinical parameters were used as input variables to 
construct the SVM and ANN models.
Although many models or nomograms are available to the 
clinician to predict the pathologic stage and freedom from 
biochemical failure after treatment, few models are designed 
to predict the pathologic stage of prostate cancer with 
the outcome of TRUS-guided prostate biopsy (2). Because 
prostate cancer is a disease that requires more than one 
option for the physician to be able to determine diagnosis, 
staging, and treatment, it provides a good example of the 
need for a CDSS. We tried to construct CDSSs using the SVM 
and ANN models and to compare the performances of these 
models based on readily available parameters, including 
biopsy parameters. 
ANNs are computer programs that simulate some of the 
higher-level functions of the architecture of the human 
brain (11). In ANNs simple processing units (nodes) which 
simulate neurons are linked via weighted interconnections. 
The interconnection weights function as multipliers that 
simulate the connection strengths between neurons in 
an analogous biological model. The nodes are commonly 
arranged in three or more layers (input, output, and 
hidden layers). The input layer accepts the values of the 
predictor variables presented to the neural network, while 
one or more output nodes represent the predicted outputs 
(prediction of cancer or disease stages). One or more hidden 
layers of nodes link the input and output layers (2, 22).
There are several reports in which ANNs were used 
for the early detection of prostate cancer, a prostate 
rebiopsy, prostate cancer staging, or for predicting 
biochemical failure. Zlotta et al. (23) reported that the 
ANN outperformed logistic regression analysis and correctly 
predicted pathologic stage in > 90% of the validation 
patients with serum PSA levels < 10 ng/mL based on 
clinical, biochemical, and biopsy data. Babaian et al. (24) 
compared the sensitivity, specificity, and negative and 
positive predictive values between the use of a neural 
network algorithm and other PSA parameters showed that 
the ANN was significantly better in terms of specificity 
when sensitivity was constantly held at 92%. 
The use of SVM developed by Vapnik (25) has 
resulted in an advance to solve or classify pattern 
recognition problems. The aim of the SVM is to devise 
a computationally-efficient way of learning separating 
hyperplanes in a high-dimensional feature space. The SVM 
can map the input vectors into a high-dimensional feature 
space through some non-linear mapping. In this space, an 
optimal separating hyperplane is constructed. The process 
of training an SVM classifier is equivalent to finding this 
optimal hyperplane in a way that minimizes the error on the 
training dataset and maximizes the perpendicular distance 
between the decision boundary and the closest data points 
in classes (2, 26-29). The advantage of the SVM is that an 
SVM classifier depends only on the support vectors, and the 
classifier function is not influenced by the entire data set, 
as is the case for many neural network systems, including 
ANN. Another characteristic of the SVM is the possibility to 
deal efficiently with a very large number of features because 
of the exploitation of kernel functions (2, 30).
It has been shown that the empirical performance of 
SVMs is generally as good as the best ANN solutions, and 
it has been proposed that the good performance of SVMs 
results from fewer model parameters to optimize in the 
SVM approach, reducing the possibility of over-fitting the 
training data and thus increasing the actual performance. 
Chang et al. (31) reported that the classification ability of 
the SVM is nearly equal to that of the neural network model 
in imaging diagnosis of breast malignancy. According to 
their study, the training and diagnosis procedure of the SVM 
is faster and more stable than other neural network models.
In our study the CDSSs, such as a SVM or an ANN, could 
provide the probability that the patient has advanced 
prostate cancer (more than pT3a) with inputs of various 
clinical and biopsy parameters. From our results, the AUC for 
the SVM and the ANN were 0.805 and 0.719, respectively. 
There were some false-positive and -negative cases. The 
false-positive cases were due to an overestimate of the 
pre-operative stage and the false-negative cases were due 
to an underestimate of the pre-operative stage. The false-
positive cases might occur when the selected biopsy areas 
had a concentration of poorly differentiated cancer cells. 
Conversely, the false-negative cases might occur when the 
selected biopsy areas had little distribution of the poorly 
differentiated cancer cells. In the pre-operative prediction 
of advanced prostate cancer, the performance of the SVM 
was statistically superior to ANN. Based on our results, the 
CDSSs, such as a SVM or an ANN derived from computerized 
machine learning techniques, make it possible for the 
clinician to predict the pathologic stage more objectively 
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without biases and to determine adequate management 
planning for biopsy-proven prostate cancer patients. It is 
expected that the SVM aids the physician in choosing the 
best treatment option.
Our study had several limitations. First, each process to 
acquire the clinical and biopsy parameters was performed 
by one analyst. This might be influenced by individual 
experience, skill, and knowledge. Moreover, the techniques 
used by the same expert might undergo subtle changes 
with time. Second, any predictive model based on maximum 
cancer length should be further validated and modified 
because the quantity of the tissue core invaded by a 
tumor depends on several other factors, including tumor 
and prostate volume, tumor distribution, and the biopsy 
procedure (13, 32).
Despite the limitations to the current study, our CDSSs 
for pre-operative prediction of advanced prostate cancer 
with input data of TRUS-guided prostate biopsy and 
clinical parameters can offer the physician and the patient 
information regarding tumor staging. Based on our results, 
with respect to the pre-operative prediction of advanced 
prostate cancer, the performance of the SVM was superior to 
ANN.
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